All acid-suppressing medicines (PPIs and H2 blockers) are permanently forbidden; heartburn should stop through the diet, not through drugs.

Original statement

أدوية مثبطات الحموضة ممنوعة عندي بشكل دائم — هي سموم تسبب الكبد الدهني والقولون العصبي، وتمنع الجسم من الاستفادة من الطعام وامتصاص الحديد وفيتامين ب12 والمعادن، وتعالج الأعراض فقط بينما تفاقم المشاكل الأساسية من نمو بكتيري وسوء هضم.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

All acid-suppressing medicines (PPIs and H2 blockers) are permanently forbidden; heartburn should stop through the diet, not through drugs.

Origin

Source status

Archive quote (no location given)

Attribution

Elawady (archive paraphrase; source video not given)

Origin

https://eltayebat.com/rule/acid-blockers/

Attribution uncertainty

The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): found_close_paraphrase. 'Acid suppressants are a deadly poison' (bmiYyChQ310), 'stop them permanently' (MoSROUaIDhs) and 'Controloc is forbidden' (hf_DXalTTDc) are found. H2 blockers were not checked specifically. Other parts of the archive quote (fatty liver, irritable bowel, iron/B12 absorption, bacterial overgrowth) were not found in a single passage with acid suppressants and may be the archive's summary.

Claimed mechanism

Acid is beneficial; suppression is harmful; diet removes the cause.

Claimed health effect

Better health without acid medicines.

Population concerned

Everyone following the system.

Geographic restriction by Elawady

none found

Diverging source versions

Scientific assessment

False – The statement contradicts the robust evidence.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

A permanent ban on all acid medicines for everyone.

2. What is demonstrably correct?

Overuse of PPIs without an indication is a real problem and guidelines recommend de-prescribing when there is no indication (see C-PPI-11).

3. What is wrong or exaggerated?

A universal ban ignores proven indications in which PPIs prevent serious harm, including bleeding prevention in people on antiplatelet drugs and maintenance in Barrett's oesophagus or severe erosive oesophagitis (AGA 2022 BPA 4–7; Farrell 2017 excludes these groups from de-prescribing).

4. What remains unclear?

Diet and weight loss can improve reflux symptoms, but how far they can replace drugs differs between patients.

5. Which studies support it?

None for the universal ban.

6. Which studies contradict it?

COGENT (I-PPI-08), AspECT (I-PPI-09; high- vs low-dose esomeprazole with no PPI-free arm, benefit driven by mortality and high-grade dysplasia with no difference in adenocarcinoma, 40/1270 vs 41/1265; it shows long-term high-dose PPI is well tolerated and modestly beneficial, not a direct comparison with stopping PPIs), ACG 2022 (I-PPI-10), AGA 2017 (I-PPI-03), AGA 2022 (I-PPI-04), Farrell 2017 (I-PPI-05).

7. What applies to Germany and Europe?

German and European guidelines likewise reserve long-term PPI therapy for defined indications; over-the-counter PPIs are meant for short-term use.

8. What is known about Egypt?

Elawady states the ban applies to everyone; the mytayibat list adds advice to consult one's own doctor.

9. What practical conclusion is appropriate?

PPIs should be given only for a clear reason and reviewed regularly, but in several conditions they prevent bleeding and complications and should not be stopped without medical advice.

Assessment details

Rationale for certainty of evidence

For specific indications there is randomised evidence of benefit: omeprazole reduced upper GI bleeding in patients on dual antiplatelet therapy (COGENT, HR 0.34; overt bleeding HR 0.13); high-dose versus low-dose esomeprazole improved a composite outcome in Barrett's oesophagus (AspECT, TR 1.27; no PPI-free arm, adenocarcinoma not different); PPIs are strongly recommended for healing erosive oesophagitis (ACG 2022, high-quality evidence). Guidelines say these patients should not stop PPIs.

Source quality

Archive quote, third-party food lists and several videos agree on a blanket ban; mytayibat adds 'under the supervision of your doctor'.

Regional transferability

Applies everywhere.

Individual exceptions

No exception for bleeding ulcer, anticoagulation/antiplatelet therapy, Barrett's oesophagus, severe oesophagitis, eosinophilic oesophagitis, idiopathic pulmonary fibrosis or H. pylori eradication therapy is mentioned.

Regional scope of the claim

general (biological/medical)

Last reviewed

25 October 2026 provisional

In plain language

Many people take acid blockers longer than they need, and reviewing this is sensible. But for some people these drugs are protective, for example people who take blood thinners or anti-platelet drugs and are at risk of stomach bleeding, people with a severe inflamed oesophagus, and people with Barrett's oesophagus. Randomised trials show fewer bleeds in such patients. A ban for everyone can therefore cause harm.

Studies on this claim

Regional context

Germany / EU

German and European guidelines likewise reserve long-term PPI therapy for defined indications; over-the-counter PPIs are meant for short-term use.

Egypt

Elawady states the ban applies to everyone; the mytayibat list adds advice to consult one's own doctor.

What applies in my country?

General scientific assessment

False False as a universal rule: PPIs are overused, but in defined conditions they prevent serious harm.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

1. Clopidogrel with or without omeprazole in coronary artery disease.. Bhatt DL et al.. N Engl J Med 2010 · PMID 20925534 · DOI 10.1056/NEJMoa1007964
2. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.. Jankowski JAZ et al.. Lancet 2018 · PMID 30057104 · DOI 10.1016/S0140-6736(18)31388-6
3. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.. Katz PO et al.. Am J Gastroenterol 2022 · PMID 34807007 · DOI 10.14309/ajg.0000000000001538
4. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.. Freedberg DE et al.. Gastroenterology 2017 · PMID 28257716 · DOI 10.1053/j.gastro.2017.01.031
5. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.. Targownik LE et al.. Gastroenterology 2022 · PMID 35183361 · DOI 10.1053/j.gastro.2021.12.247
6. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.. Farrell B et al.. Can Fam Physician 2017 · PMID 28500192